Cartesian Therapeutics Inc
NASDAQ:RNAC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.7
40.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Cartesian Therapeutics Inc
Wall Street
Price Targets
RNAC Price Targets Summary
Cartesian Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
RNAC
is 43.86 USD
with a low forecast of 39.39 USD and a high forecast of 52.5 USD.
RNAC Last Price Targets
Cartesian Therapeutics Inc
The latest public price target was made on Aug 9, 2024 by
Mitchell Kapoor
from
H.C. Wainwright
,
who expects
RNAC
stock to
rise by 169%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Mitchell Kapoor
H.C. Wainwright
|
45
USD
Upside 169% |
1 month ago
Aug 9, 2024
|
Cartesian Therapeutics price target lowered to $45 from $49 at H.C. Wainwright
TheFly
|
John Newman
Canaccord Genuity
|
43
USD
Upside 157% |
2 months ago
Jul 3, 2024
|
Cartesian Therapeutics price target raised to $43 from $38 at Canaccord
TheFly
|
Uy Ear
Mizuho Securities
|
40
USD
Upside 140% |
3 months ago
May 24, 2024
|
Mizuho Resumes Cartesian Therapeutics (RNAC) at Buy
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is RNAC's stock price target?
Price Target
43.86
USD
According to Wall Street analysts, the average 1-year price target for
RNAC
is 43.86 USD
with a low forecast of 39.39 USD and a high forecast of 52.5 USD.
What is Cartesian Therapeutics Inc's Revenue forecast?
Projected CAGR
-11%
For the last 8 years the
compound annual growth rate for
Cartesian Therapeutics Inc's revenue is
20%.
The projected
CAGR
for the next 3 years is
-11%.
You don't have any saved screeners yet
